Litcius/Paper detail

Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics

Nancy Risebrough, Timothy Baker, Lirong Zhang, Sarah Ali, Michael Radin, Tam Dang‐Tan

2021Clinical Therapeutics12 citationsDOI

Topics & Concepts

SemaglutideMedicineLiraglutideDulaglutideType 2 diabetesDiabetes mellitusInternal medicineEndocrinologyDiabetes Treatment and ManagementHyperglycemia and glycemic control in critically ill and hospitalized patientsDiabetes Management and Research
Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics | Litcius